Tg Therapeutics (TGTX) Accumulated Expenses (2010 - 2026)

Tg Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $18.7 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 263.29% year-over-year to $18.7 million in Q1 2026; TTM through Mar 2026 was $18.7 million, a 263.29% increase from a year earlier, with the FY2025 full-year figure at $21.8 million, up 43.89% from the prior year.
• Accumulated Expenses retreated to $18.7 million in Q1 2026 per TGTX's latest filing, from $21.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $21.8 million in Q4 2025 and bottomed at $1.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $8.3 million (2023), against an average of $9.1 million.
• Across the five-year window, Accumulated Expenses sank 66.57% in 2022 and surged 263.29% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $8.4 million in 2022, then soared by 44.35% to $12.2 million in 2023, then grew by 24.75% to $15.2 million in 2024, then jumped by 43.89% to $21.8 million in 2025, then slipped by 14.62% to $18.7 million in 2026.
• Per Business Quant, the three latest TGTX Accumulated Expenses figures stand at $18.7 million (Q1 2026), $21.8 million (Q4 2025), and $15.0 million (Q3 2025).